Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepcortespenlisimut-L in advanced hepatocellular carcinoma
NCT02232490Phase 3Unknown
- Sponsor
- Immunitor Inc.
- Start
- Jan 2015
- Primary completion
- Nov 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing hepcortespenlisimut-L with Placebo (2 arms). Primary endpoint: Changes in plasma Alpha-Fetoprotein at 3 months. Status: unknown.
02
Drugs
hepcortespenlisimut-l
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02232490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02232490.